Search research articles
Contact Us
Filters
Showing results (11-20 of 174) with videos related to
Page
of 18
Sort By:
Health Economics
|
July 28, 2010
Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods
Mark Sculpher, Karl Claxton
Pharmacoeconomics
|
February 8, 2006
Better analysis for better decisions: has pharmacoeconomics come of age?
Michael Drummond, Mark Sculpher
Pharmacoeconomics
|
January 14, 2020
After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Mark Sculpher, Stephen Palmer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 11, 2005
Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
Mark Sculpher, Karl Claxton
Medical Care
|
August 2, 2005
Common methodological flaws in economic evaluations
Michael Drummond, Mark Sculpher
Practical Neurology
|
May 27, 2008
Quality-adjusted life years
Yolanda Bravo Vergel, Mark Sculpher
Family Practice
|
July 14, 2006
Making decisions under uncertainty--the role of probabilistic decision modelling
Yolanda Bravo Vergel, Mark Sculpher
Social Science & Medicine (1982)
|
June 13, 2002
Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions
Mark Sculpher, Amiram Gafni, Ian Watt
Lancet (London, England)
|
September 21, 2002
A rational framework for decision making by the National Institute For Clinical Excellence (NICE)
Karl Claxton, Mark Sculpher, Michael Drummond
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
February 12, 2008
The value of implementation and the value of information: combined and uneven development
Elisabeth Fenwick, Karl Claxton, Mark Sculpher
Page
of 18
Search research articles
Search
Showing results (11-20 of 174) with videos related to
Sort By:
Page
of 18
Health Economics
|
July 28, 2010
Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods
Mark Sculpher, Karl Claxton
Pharmacoeconomics
|
February 8, 2006
Better analysis for better decisions: has pharmacoeconomics come of age?
Michael Drummond, Mark Sculpher
Pharmacoeconomics
|
January 14, 2020
After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Mark Sculpher, Stephen Palmer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 11, 2005
Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
Mark Sculpher, Karl Claxton
Medical Care
|
August 2, 2005
Common methodological flaws in economic evaluations
Michael Drummond, Mark Sculpher
Practical Neurology
|
May 27, 2008
Quality-adjusted life years
Yolanda Bravo Vergel, Mark Sculpher
Family Practice
|
July 14, 2006
Making decisions under uncertainty--the role of probabilistic decision modelling
Yolanda Bravo Vergel, Mark Sculpher
Social Science & Medicine (1982)
|
June 13, 2002
Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions
Mark Sculpher, Amiram Gafni, Ian Watt
Lancet (London, England)
|
September 21, 2002
A rational framework for decision making by the National Institute For Clinical Excellence (NICE)
Karl Claxton, Mark Sculpher, Michael Drummond
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
February 12, 2008
The value of implementation and the value of information: combined and uneven development
Elisabeth Fenwick, Karl Claxton, Mark Sculpher
Page
of 18